Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2016

Open Access 01-07-2016 | Letter to the Editor

Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

Authors: R. Vellucci, G. Fanelli, P. A. Cortesi, R. Pannuti, C. Peruselli, P. Romualdi, Working Group Nientemale DEI

Published in: Drugs | Issue 10/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Giusti R, Verna L, Iacono D et al. Comment on “ What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion”. Drugs. 2016;76. doi:10.​1007/​s40265-016-0593-0
2.
Working Group Nientemale DEI, Vellucci R, Fanelli G et al. What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. Drugs. 2016;76(3):315–330CrossRefPubMedCentral
3.
Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M. Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009;100(10):1566–74.CrossRefPubMedPubMedCentral
4.
Mercadante S, Costanzo BV, Fusco F, Buttà V, Vitrano V, Casuccio A. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage. 2009;38(4):554–60.CrossRefPubMed
5.
Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, SlamaO, Korhonen T, Filbet M, Poulain P, Mystakidou K, Ardavanis A, O’Brien T,Wilkinson P, Caraceni A, Zucco F, Zuurmond W, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund KF, Stenberg M. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag.2013;46(5):619–28.
6.
Bedard G, Davies A, McDonald R, Hawley P, Buchanan A, Popovic M, Wong E, Chow E. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. Support Care Cancer. 2015;23(3):791–6.CrossRefPubMed
7.
Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of under-treatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985–91.CrossRefPubMedPubMedCentral
8.
Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V. Apolone G; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011;27(1):9–18.CrossRefPubMed
9.
Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag. 2014;47(4):772–785.e5.
10.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8.
11.
Paolo A. Cortesi, Flavia Kheiraoui, Giuseppe Casale, Carlo Favaretti, Giovanni Guarrera, Pierangelo Lora Aprile, Patrizio Piacentini, Lorenzo G Mantovani. Budget impact analysis del fentanyl citrato sublinguale nella gestione del breakthrough cancer pain. 2015;4(3). http://​www.​ijph.​it/​pdf/​99/​014.​pdf. Accessed 30 Apr 2016.
12.
Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care. 2008;14(5 Suppl 1):S129–40.PubMed
13.
Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27(2):167–75.CrossRefPubMed
14.
Vellucci R, Mediati RD, Gasperoni S, Piergallini LM, Valentino MC, Bruno GM, Di Matteo S, Colombo GL. Pharmacoeconomic considerations about breakthrough cancer pain. Value Health. 2015;18(7):A665–6.CrossRefPubMed
Metadata
Title
Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
Authors
R. Vellucci
G. Fanelli
P. A. Cortesi
R. Pannuti
C. Peruselli
P. Romualdi
Working Group Nientemale DEI
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0594-z

Other articles of this Issue 10/2016

Drugs 10/2016 Go to the issue

Adis Drug Evaluation

Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome

Adis Drug Evaluation

Sugammadex: A Review of Neuromuscular Blockade Reversal

Leading Article

Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions

AdisInsight Report

Pimavanserin: First Global Approval

Adis Drug Evaluation

Secukinumab: A Review in Ankylosing Spondylitis

Review Article

Fimasartan: A New Angiotensin Receptor Blocker